Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis

Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established. In this study, an observational, retrospective and multi-center analysis was performed to explore the decitabine schedule f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiao, Song, Qiang, Chen, Yu, Chang, Chunkang, Wu, Dong, Wu, Lingyun, Su, Jiying, Zhang, Xi, Zhou, Liyu, Song, Luxi, Zhang, Zheng, Xu, Feng, Hou, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991661/
https://www.ncbi.nlm.nih.gov/pubmed/24748149
http://dx.doi.org/10.1371/journal.pone.0095473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991661/
https://www.ncbi.nlm.nih.gov/pubmed/24748149
http://dx.doi.org/10.1371/journal.pone.0095473

Ejemplares similares